Navigation Links
Arpida Interim Results for six Months to 30 June 2007
Date:8/28/2007

ults

In the first half of 2007, revenues of CHF 0.1 million were generated, related to contract research carried out for third parties.

Total operating expenses increased to CHF 33.7 million for the first six months of 2007.Of these expenses CHF 2.7 million relate to IFRS 2 non-cash charges for options accounting whereas this charge was CHF 1.0 million in the first half of 2006.

In the first half of 2007, 82% of the total operating expenses or CHF 27.7 million (first half of 2006: CHF 23.9 million) was spent on research & development, a substantial part of which was related to the phase III clinical trial programme with intravenous iclaprim.

Management and general expenses were CHF 6.0 million in the first half of 2007 (first half of 2006: CHF 4.6 million), thus remaining at a low level relative to the total operating expenses.

Financial income rose from CHF 0.6 million to CHF 0.8 million. This increase is mainly due to higher levels of cash invested and higher interest rates in Swiss Francs money market accounts. Financial expenses increased to CHF 0.8 million due to unrealised currency translation differences on inter-company relationships and CHF 0.3 million of realised exchange losses. On balance, the net financial result amounts to zero.

Balance sheet / cash flow

Cash and financial investments stood at CHF 94.7 million as per 30 June 2007, an increase of CHF 21.9 million relative to the situation at year-end 2006. The funds are held in current and money market accounts with leading banks.

Cash used in operating activities amounted to CHF 29.8 million (first half of 2006: CHF 24.0 million), while investing activities required CHF 0.9 million, compared with CHF 2.8 million in the first half of 2006. Financing activities amounted to CHF 52.2 million, mainly reflecting the proceeds of the share issue of March 2007.

In the share placing of March 2007, 1.7 million registered common shares from authorised capital w
'/>"/>

SOURCE Arpida
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Effects of Thermal Cycler Well-To-Well Temperature Uniformity on PCR Results
2. HotMasterAn innovative Hot Start/Cold Stop technology for better PCR* results
3. Achieving Reliable Protein Quantitation Results Using ICAT Reagents, MALDITOF Mass Spectrometry, and Advanced Data Interpretation Tool
4. How Best Buy said bye to burnout, hello to results
5. Economic survey reveals better 2006 results
6. Third Wave Reports Third-Quarter Financial Results
7. Tech Digest: Merge eMed product updates; Renaissance Learning 3rd qtr results
8. Midwest small-cap life sciences turn in mixed third-quarter results
9. To boost advertising results, consider improving your web site
10. RedPrairie Reports Strong Results
11. 2003 Biotech Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... The next implants made from the PEEK-OPTIMA® ... (European) approval. The CE mark is necessary for distributing ... the European Union. Following the Class IIb approval route, ... supplied by the Turkey-based company Osimplant for the treatment ... Expandable Bladed HA PEEK Cage line of spinal implants, ...
(Date:3/4/2015)... , March 4, 2015 The UPMC Center ... 2015 Fellows in the Emerging Leaders in Biosecurity Initiative ... leaders in the field of biosecurity, UPMC has selected ... a wide array of backgrounds, including biological science, medicine, ... "With the vision and support of ...
(Date:3/4/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/jspg2c/global_biologics ) ... Biologics and Biosimilars Industry Report 2015" report ... Global Biologics and Biosimilars Industry Report 2015 is ... state of the biologics and biosimilars industry. ... the industry including definitions, classifications, applications and industry ...
(Date:3/4/2015)... 4, 2015 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... focused on the development and commercialization of innovative ... pain, today announced that it will release fourth ... close on Monday, March 9th, 2015. AcelRx management ... p.m. Eastern Time (1:30 p.m. Pacific Time) on ...
Breaking Biology Technology:Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3Global Biologics and Biosimilars Industry Report 2015-2020 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3
... ZURICH, Switzerland, January 28 Nycomed has ... exclusive development, marketing and,commercialisation rights for Ciclesonide ... corticosteroid with a novel principle of action. ... Inhalation Aerosol for the,treatment of asthma and ...
... Better Option for Humans, EGG HARBOR TOWNSHIP, ... first time, The British Institute of Homeopathy, U.S.A. ... U.S. medical and,homeopathic practitioners for a low-introductory cost ... therapy is more advantageous because,it does not carry ...
... CINCINNATI, Jan. 28 Kendle (Nasdaq: KNDL ... that Chairman and Chief Executive Officer Candace Kendle, ... The conference,will be held at the Langham Hotel ... for Wednesday, Jan. 30 at 1:30 p.m. Eastern ...
Cached Biology Technology:Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 2Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 3Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 4Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 5Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 6Kendle to Present at the Wachovia 2008 Healthcare Conference 2
(Date:1/22/2015)... ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the addition of ... to their offering. , The primary goal ... who she/he is claiming to be, and for this purpose, ... characteristics, such as fingerprint, hand or palm print, iris, face ...
(Date:1/22/2015)... /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry news, ... website design. "When we launched FindBiometrics 12 years ... O,Neill , founder and CEO of FindBiometrics. "Now it,s maturing ... the key players on a very broad scale.  We are ...
(Date:1/22/2015)... 2015 Technology Showcase, Hall E -   EyeLock Inc. ... announced it will showcase its EyeLock ID technology integrated in ... of Energy,s Oak Ridge National Laboratory (ORNL) at ... iris identity authentication technology is being used to validate the ...
Breaking Biology News(10 mins):Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... what looks to be a nice piece of certified sustainable ... what you,re getting. Unfortunately, things aren,t always what they seem, ... eco-labeled Chilean sea bass and report their findings in the ... Press publication. "We found that, for fish purchased ...
... population biologist Peter Marko and his colleagues have found that ... claimed to be. Some fish sold in stores are not ... not Chilean sea bass at all. The research by ... Aug. 23 edition of Current Biology (Marko et ...
... , This press release is available in ... (USDA) scientists working with the University of Illinois at ... reduce soybean yields by an average 23 percent. ... Agricultural Research Service Soybean/Maize Germplasm, Pathology, and Genetics Research ...
Cached Biology News:Eco-labeled seafood is not always what it seems 2Breeding ozone-tolerant crops 2
... CE-based system provides clear advantages over ... load, gene expression), mutation analysis, and ... system with microplate connectivity is ideal ... quality control. The P/ACE Series ...
The imaging screen-K (Kodak), is a 35 x 43 cm storage phosphor screen that is used for the quantitation and imaging of 32P, 33P, 35S, 14C, and 3H....
The filter 695RDF55 Reflect 635 for the Molecular Imager FX is a band pass filter for Cy5 and Alexa Fluor 635 dyes....
... Kit is a 2-color staining method for ... to detect apoptotic cells by flow cytometry. ... required for measuring apoptosis in cells, including ... reagent performance; washing, reaction and rinsing buffers ...
Biology Products: